2026年美国临床肿瘤学会（ASCO）年会将于5月29日至6月3日在美国芝加哥举行。作为全球规模最大的肿瘤学研究盛会之一，此次大会云集全球肿瘤学领域的顶尖专家学者，共同探讨和分享最新的研究成果、治疗方法和临床实践经验。目前大会官网已公布摘要标题，【肿瘤资讯】特此整理了本届ASCO大会中泌尿肿瘤治疗领域的重磅口头报告（Oral, Rapid Oral以及Clinical Science Symposium）的最新研究成果，以飨诸君。
Plenary Session
摘要号：LBA1
英文标题：Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study.
中文标题：围手术期（新辅助及辅助）阿帕他胺（APA）+ 雄激素剥夺治疗（ADT）对比安慰剂（PBO）+ ADT 联合根治性前列腺切除术（RP）治疗高风险局限性或局部晚期前列腺癌（HR LPC/LAPC）：PROTEUS 3期研究的最终分析。
讲者：Mary-Ellen Taplin
Clinical Science Symposium
前列腺癌
摘要号：5009
英文标题：Safety and dosimetry of 177Lu-rosopatamab tetraxetan plus SoC in patients with metastatic castration-resistant prostate cancer: Preliminary results from part 1 of phase 3 ProstACT Global study.
中文标题：177Lu-rosopatamab tetraxetan联合标准治疗在转移性去势抵抗性前列腺癌患者中的安全性与剂量学研究：III期ProstACT Global研究第1部分的初步结果
讲者：Pedro C. Barata, MD, MSc, FACP
摘要号：5010
英文标题：AcTION: Phase 1 study of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) in men with metastatic castration-resistant prostate cancer (mCRPC) with or without prior [177Lu]Lu-PSMA (177Lu-PSMA) radioligand therapy (RLT).
中文标题：AcTION：[225Ac]Ac-PSMA-617 在既往接受或未接受过 [177Lu]Lu-PSMA 放射配体治疗的转移性去势抵抗性前列腺癌患者中的 1 期研究
讲者：Louise Emmett, MD, PhD, MBChB, FRACP
摘要号：5011
英文标题：CONVERGE-01 part 3: Ac-225 rosopatamab tetraxetan (CONV01-α) in Lu-PSMA-pretreated metastatic castration-resistant prostate cancer (mCRPC).
中文标题：CONVERGE-01研究part 3：Ac-225 rosopatamab tetraxetan(CONV01-α) 用于经 Lu-PSMA 预处理的转移性去势抵抗性前列腺癌
讲者： Michael J. Morris, MD, FASCO
尿路上皮癌
摘要号：4504
英文标题：Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.
中文标题：RAD-IO研究的可行性与安全性结果：一项评估度伐利尤单抗联合同步放化疗（5-氟尿嘧啶+丝裂霉素C）治疗肌层浸润性膀胱癌的多阶段试验
讲者：Nicholas David James, PhD, MBBS, FRCP
摘要号：4510
英文标题：Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: Phase 3 KEYNOTE-905 study.
中文标题：新辅助及辅助维恩妥尤单抗联合帕博利珠单抗治疗不适合顺铂的肌层浸润性膀胱癌患者的健康相关生活质量分析：III期KEYNOTE-905研究
讲者：Peter H. O'Donnell, MD
肾癌
摘要号：LBA4511
英文标题：Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial.
中文标题：RAMPART 研究中度伐利尤单抗单药治疗对比主动监测用于切除后原发性肾细胞癌：一项国际性、3 期、随机对照试验
讲者：James M.G. Larkin, MD, PhD
摘要号：4512
英文标题：Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma.
中文标题：肾细胞癌患者接受帕博利珠单抗辅助治疗后的决策后悔及毒性感知
讲者：Elizabeth Nally, MBBS
Oral Abstract Session
前列腺癌
摘要号：5000
英文标题：Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification in high-risk prostate cancer: A combined analysis of NRG/RTOG 9202, 9413, 9902, and 0521.
中文标题：临床-转录组风险分层指导阿比特龙强化治疗高危前列腺癌：NRG/RTOG 9202、9413、9902 和 0521 的联合分析
讲者：Krishnan R. Patel, MD, MHS
摘要号：5001
英文标题：Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.
中文标题：评估 Decipher 前列腺基因组分类器 >0.85 识别在雄激素剥夺疗法联合恩扎卢胺基础上加入多西他赛获益患者的能力：来自 ENZAMET 研究的 1B 级证据
讲者：Christopher Sweeney, MBBS
摘要号：5004
英文标题：A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / Alliance A032101).
中文标题：转移性激素敏感性前列腺癌中对雄激素受体通路抑制剂反应极佳的患者中中断雄激素剥夺治疗的 2 期试验（A-DREAM / Alliance A032101）
讲者：Atish Dipankar Choudhury, MD, PhD
摘要号：5005
英文标题：Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology.
中文标题：达罗他胺对比恩扎卢胺的认知影响：来自肿瘤学临床试验联盟的随机临床试验 ARACOG（AFT-47）结果
讲者：Alicia K. Morgans, MD, MPH, FASCO
摘要号：5006
英文标题：Final results from ZZFIRST: A randomized phase 2 trial of enzalutamide (EZ) and talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC).
中文标题：ZZFIRST 研究的最终结果：恩扎卢胺联合他拉唑帕利治疗转移性激素初治性前列腺癌的随机 2 期试验
讲者：Joaquin Mateo, MD, PhD
摘要号：LBA5007
英文标题：TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.
中文标题：TALAPRO-3：他拉唑帕利 + 恩扎卢胺对比安慰剂 + 恩扎卢胺治疗携带同源重组修复基因改变的转移性去势敏感性前列腺癌患者
讲者：Neeraj Agarwal, MD, FASCO
摘要号：5008
英文标题：Fuzuloparib combined with abiraterone acetate and prednisone (AA-P) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Interim results from the FUZUPRO trial.
中文标题：氟唑帕利联合醋酸阿比特龙和泼尼松一线治疗转移性去势抵抗性前列腺癌：FUZUPRO 试验的中期结果
讲者：叶定伟，复旦大学附属肿瘤医院
尿路上皮癌
摘要号：4506
英文标题：Perioperative SHR-A2102, a novel nectin-4–targeted antibody-drug conjugate, in combination with adebrelimab for patients (pts) with muscle-invasive bladder cancer: Results from a phase 2/3 study.
中文标题：新型 nectin-4 靶向抗体药物偶联物 SHR-A2102 联合阿得贝利单抗围手术期治疗肌层浸润性膀胱癌患者：一项 2/3 期研究
讲者：叶定伟 复旦大学附属肿瘤医院
摘要号：4507
英文标题：Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.
中文标题：维恩妥尤单抗联合帕博利珠单抗对比化疗用于既往未经治疗的局部晚期或转移性尿路上皮癌：EV-302 3 期研究的 3.5 年随访和应答分析
讲者：Thomas Powles
摘要号：4503
英文标题：Intravesical recombinant BCG combined with chemo-immunotherapy (chemo-IO) as perioperative therapy for patients with muscle-invasive bladder cancer (MIBC): Primary analysis of SAKK 06/19.
中文标题：膀胱内灌注重组卡介苗联合化学免疫治疗（chemo-IO）作为肌层浸润性膀胱癌（MIBC）患者的围手术期治疗：SAKK 06/19研究的初步分析
讲者：Richard Cathomas
摘要号：4508
英文标题：Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.
中文标题：靶向Nectin-4的抗体药物偶联物LY4052031在晚期或转移性尿路上皮癌患者中的I期研究NEXUS-01的初步结果
讲者：Gopa Iyer
肾癌
摘要号：4500
英文标题：A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).
中文标题：镭-223 联合卡博替尼治疗伴骨转移的肾细胞癌患者的随机 2 期试验（RADICAL / Alliance A031801）
讲者：Rana R. McKay, MD, FASCO
摘要号：4501
英文标题：A prospective, multi-center, phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non–clear cell renal cell carcinoma.
中文标题：一项一线卡度尼利单抗联合阿昔替尼治疗晚期非透明细胞肾细胞癌的前瞻性、多中心、Ib/II期试验
讲者：胡旭 四川大学华西医院
摘要号：4502
英文标题：ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.
中文标题：KEYNOTE-564 试验中接受帕博利珠单抗或安慰剂辅助治疗的肾细胞癌参与者的 ctDNA 分析
讲者：Toni K. Choueiri, MD, FASCO
睾丸癌
摘要号：LBA5003
英文标题：First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.
中文标题：SWOG S1823 的首次中期分析：循环 microRNA 371a-3p 在预测早期睾丸癌患者活动性生殖细胞恶性肿瘤中的操作特征
讲者：Lucia Nappi, MD, PhD, FRCPC
Rapid Oral Abstract Session
前列腺癌
摘要号：LBA5012
英文标题：Early results of COMPPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer.
中文标题：COMPPARE 研究的早期结果：前列腺癌质子与光子放射治疗结局的前瞻性比较
讲者：Tanya B. Dorff, MD, FASCO
摘要号：5013
英文标题：Genomic classifier–driven NCCN risk reclassification to track distinct transcriptomic signatures in early prostate cancer.
中文标题：基因组分类器驱动的 NCCN 风险重新分类以追踪早期前列腺癌中不同的转录组特征
讲者：Daniel Keizman, MD
摘要号：5014
英文标题：A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC).
中文标题：一项评估 ABBV-969 在转移性去势抵抗性前列腺癌患者中的安全性、药代动力学和疗效的首次人体 1 期研究
讲者：Tanya B. Dorff, MD, FASCO
摘要号：5015
英文标题：Phase 2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
中文标题：YL201（一种抗 B7H3 抗体药物偶联物）在多线治疗转移性去势抵抗性前列腺癌中的 2 期研究
讲者：叶定伟，复旦大学附属肿瘤医院
摘要号：5016
英文标题：Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP).
中文标题：针对神经内分泌或侵袭性变异型转移性前列腺癌患者的化学免疫疗法 2 期多中心试验（CHAMP）
讲者：Andrew J. Armstrong, MD, MS
摘要号：5017
英文标题：PROTRACT: A randomized phase II trial comparing ctDNA-guided biomarker directed therapy vs patient/clinician’s choice for metastatic castration resistant prostate cancer (mCRPC) progressing after abiraterone plus prednisone (AAP).
中文标题：ROTRACT：一项随机 II 期试验，比较 ctDNA 指导的生物标志物导向治疗与患者/临床医生选择治疗用于阿比特龙联合泼尼松治疗后进展的转移性去势抵抗性前列腺癌
讲者：Corinne Maurice-Dror, MD
摘要号：5018
英文标题：Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201.
中文标题：基于循环肿瘤 DNA 的临床-遗传预后模型预测转移性去势抵抗性前列腺癌患者影像学无进展生存期：Alliance A031201 分析
讲者：Susan Halabi, PhD, FASCO
摘要号：5019
英文标题：Canadian Cancer Trials Group (CCTG) study PR21 (PLUDO): Results of crossover treatment from a randomized trial of 177Lu-PSMA-617 (LuP) vs docetaxel (DOC) in patients with metastatic castration-resistant prostate cancer (mCRPC).
中文标题：加拿大癌症试验组 PR21 研究：177Lu-PSMA-617 对比多西他赛治疗转移性去势抵抗性前列腺癌随机试验的交叉治疗结果
讲者：Kim N. Chi, MD
摘要号：5020
英文标题：Subgroup analyses by disease volume and de novo/recurrent mHSPC in the PSMAddition study of [177Lu]Lu-PSMA-617.
中文标题：PSMAddition 研究中 [177Lu]Lu-PSMA-617 按疾病负荷和初发/复发转移性激素敏感性前列腺癌的亚组分析
讲者：Fred Saad, MD, FRCS
尿路上皮癌
摘要号：4516
英文标题：Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele; BT8009) + pembrolizumab in patients (pts) with previously untreated locally advanced/metastatic urothelial carcinoma (la/mUC).
中文标题：Duravelo-2 的中期分析结果：Zelenectide pevedotin + 帕博利珠单抗用于既往未经治疗的局部晚期/转移性尿路上皮癌患者
讲者：Yohann Loriot, MD, PhD
摘要号：4514
英文标题：MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032901).
中文标题：MAIN-CAV：一线铂类化疗后卡博替尼联合阿维鲁单抗对比阿维鲁单抗维持治疗局部晚期/转移性尿路上皮癌的 III 期随机试验（Alliance A032901）
讲者：Shilpa Gupta, MD
摘要号：4515
英文标题：Phase II study of frontline gemcitabine, 5-fluorouracil/leucovorin, and cisplatin (GemFLP) in advanced urachal and non-urachal urinary tract adenocarcinoma.
中文标题：吉西他滨、5-氟尿嘧啶/亚叶酸钙联合顺铂方案一线治疗晚期脐尿管及非脐尿管尿路腺癌的II期研究
讲者：Emanuele Crupi, MD
摘要号：4517
英文标题：Initial results from EXCEED, a phase 1 study of LY4101174, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.
中文标题：靶向Nectin-4的抗体药物偶联物LY4101174在晚期或转移性尿路上皮癌患者中的I期研究EXCEED的初步结果
讲者：Xin Gao, MD
摘要号：4624
英文标题：Durvalumab (D) in combination with BCG induction and maintenance (I + M) therapy for BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.
中文标题：度伐利尤单抗联合BCG诱导及维持治疗用于BCG初治、高危非肌层浸润性膀胱癌：POTOMAC研究的5年总生存分析及患者报告结局
讲者：Maria De Santis, MD
摘要号：4518
英文标题：Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Follow-up results from a phase 1b/2 study.
中文标题：Bulumtatug fuvedotin（BFv；9MW2821）联合特瑞普利单抗治疗局部晚期或转移性尿路上皮癌（la/mUC）患者：一项 1b/2 期研究的随访结果
讲者： 盛锡楠 北京大学肿瘤医院
肾癌
摘要号：4520
英文标题：Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC): A collaborative multi-institutional study.
中文标题：基于panitumumab的EGFR阻断治疗在SMARCB1缺失性肾髓质癌中的前瞻性临床活性及临床前基础：一项多机构合作研究
讲者：Pavlos Msaouel, MD, PhD
摘要号：4521
英文标题：Final results of a phase 2 trial of cabozantinib plus nivolumab (CaboNivo) in patients with non–clear cell renal cell carcinoma (nccRCC).
中文标题：卡博替尼联合纳武利尤单抗治疗非透明细胞肾细胞癌患者的 2 期试验最终结果
讲者：Darren R. Feldman, MD
排版编辑：肿瘤资讯-CY
苏公网安备32059002004080号
